• Entertainment
  • Finance
  • Marketing
  • Real Estate
  • Technology
  • Social
National Journal Community Of e-Experts
Finance

Sage Therapeutics Slumps As Biogen Deal May Dampen M&A Hopes

By Kurt Osterberg · On April 20, 2018

Weakness in shares of Sage Therapeutics (SAGE) may be related to news that Biogen (BIIB) and Ionis Pharmaceuticals (IONS) have expanded their strategic collaboration through a new ten-year collaboration agreement, which may be read by some market participants as lowering the odds for M&A action related to Sage.

Under the terms of the collaboration, Biogen will pay Ionis $1B in cash, which will include $625M to purchase 11,501,153 shares of Ionis common stock at an approximately 25% cash premium, and a $375M upfront payment. On April 24, 2017, Sage announced the appointment of Michael Cloonan as Chief Business Officer. Cloonan had come to Sage from Biogen, where he worked for 14 years. On the date of that announcement, Adam Feuerstein of STAT tweeted, “$SAGE expands exec team, including former $BIIB – er Michael Cloonan as new Chief Business Officer. Stand down on $SAGE takeout for now.” More recently, on April 10, 2018, shares of Sage has spiked higher in afternoon trading amid rumors of the company canceling from a planned presentation. A spokesperson for Sage Therapeutics told The Fly the company “cancelled participation in the JPMorgan meeting due to some travel logistics issues.” In March, Canaccord analyst Sumant Kulkarni had assumed Sage Therapeutics with a Buy rating, citing among other things “a high scarcity value in its robust/ripening CNS platforms.”

In midday trading, Sage shares are down $17.90, or 10.5%, to $151.77.

Print Friendly, PDF & Email

Share Tweet

Kurt Osterberg

You Might Also Like

  • Finance

    How To Earn A 10% Yield On Cost From PepsiCo Dividends

  • Finance

    Extreme Cold Weather Forecast Puts Natural Gas ETFs In Focus

  • Finance

    How To Trade Options

Top Finance

  • Dollar General (DG) Q2 Earnings And Revenues Surpass Estimates Dollar General (DG) Q2 Earnings And Revenues Surpass Estimates
  • Samsung Galaxy Note 9 Review Samsung Galaxy Note 9 Review
  • USD/CAD Forecast October 22-26 – Will The Canadian Dollar Rise On The Rate Hike USD/CAD Forecast October 22-26 – Will The Canadian Dollar Rise On The Rate Hike
  • Extreme Cold Weather Forecast Puts Natural Gas ETFs In Focus Extreme Cold Weather Forecast Puts Natural Gas ETFs In Focus
  • Chart: Amazon’s Dominance In Ecommerce Chart: Amazon’s Dominance In Ecommerce

New Posts

  • How To Earn A 10% Yield On Cost From PepsiCo Dividends

    How To Earn A 10% Yield On Cost From PepsiCo Dividends

    October 21, 2018
  • Extreme Cold Weather Forecast Puts Natural Gas ETFs In Focus

    Extreme Cold Weather Forecast Puts Natural Gas ETFs In Focus

    October 21, 2018
  • How To Trade Options

    How To Trade Options

    October 21, 2018
  • Adding To Merkel’s Woes: SPD’s Collapse In Germany, Greens The New Left Darlings

    Adding To Merkel’s Woes: SPD’s Collapse In Germany, Greens The New Left Darlings

    October 20, 2018
  • Self Sufficiency Over Adversity

    Self Sufficiency Over Adversity

    October 20, 2018
  • About
  • Contact Us
  • Privacy & Policy
  • Sitemap
  • Terms of use

Copyright © 2018 NJCEE. All Rights Reserved.